Collectively, our data indicated that modulation of glutamine fate might be of therapeutic value for many types of cancer, with the potential antitumor effect possibly being predictable on the basis of the endogenous expression levels of GLS1 and PPAT. The gene discussed is PPAT; the disease is cancer.